Please assess the completion status of the following clinical trial:

Trial Title: UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria~* Newly diagnosed Age-related Macular Degeneration (AMD)~* No previous treatment received for diagnosed AMD~* Visual Acuity 6/7.5 to 6/96~Key Exclusion Criteria:~* standard exclusion criteria for anti-VEGF treatment~* Visual Acuity \<6/96~* nAMD in both eyes, or any condition in other eye which may have required anti- VEGF treatment during study period~* other disease in candidate eye which could have compromised visual acuity or required medical/surgical intervention during study period~* participation to other clinical study with 'not approved' treatment within a year prior to UNRAVEL study participation.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab (Type: EXPERIMENTAL): 104 patients with an eligible study eye were randomized to be treated with Ranibizumab IVT. 0.5 mg of commercially available Ranibizumab were used for intravitreal injection adminstered by an unblinded injecting physician. 3 injections were performed (Baseline, Month 1, Month 2).
- Aflibercept (Type: ACTIVE_COMPARATOR): 101 patients with an eligible study eye were randomized to be treated with Aflibercept IVT. 2.0 mg of commercially available Aflibercept were used for intravitreal injection admistered by an unblinded injecting physician. 3 injections were performed (Baseline, Month 1, Month 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).